PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

EXAMINER: Dr. K.C. Srivastava

(Use as many sheets as necessary)

Sheet of

| Com                    | pplete if Known  |
|------------------------|------------------|
| Application Number     | 10/687,706       |
| Filing Date            | 10/20/2003       |
| -First Named Inventor  | LOSCALZO, et al. |
| Art Unit               | <b>+651</b> 1657 |
| Examiner Name          | —Te-Be-Accigned  |
| Attorney Docket Number | 102258.170US2    |

|  |              |  | U. S. PATENT I   | DOCUMENTS  |  |
|--|--------------|--|--|--|--|
| Examiner<br>Initials*  | Cite<br>No.1 | Document Number  Number-Kind Code <sup>2 (f known)</sup>   | Publication Date<br>MM-DD-YYYY   | Name of Patentee or<br>Applicant of Cited Document   | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear  |
| /K.S./   |              | <sup>US-</sup> 5,760,069   | 06/02/1998   | Lukas-Laskey et al.  |  |
| /K.S./   |              | <sup>US-</sup> 5,902,821   | 05/11/1999   | Lukas-Laskey et al.  |  |
| A STATE OF THE PARTY OF THE PAR |              | US-  |  |  | AND PROPERTY AND PARTY.  |
|  | WW. Co.      | US-  |  |  | - And the state of |
|  |              | US-  |  |  | - The state of the |
|  |              | US-  |  |  | Market Market Control of the Control |
|  |              | US-  |  |  |  |
|  |              | US-  | ***  | The state of the s |  |
|  |              | US-  |  | - The state of the |  |
| ······································   |              | US-  |  |  |  |
|  |              | US-  | The state of the s |  |  |
|  |              | US-  | AND THE PROPERTY OF THE PROPER |  |  |
|  | ļ            | US-  |  |  |  |
|  |              | US-  |  |  |  |
|  | ļ            | US-  |  |  | ***************************************  |
|  | - ANDROGEN   | AND THE PROPERTY OF THE PROPER |  |  | ***************************************  |
| - ASSESSED FOR STREET, |              | US-  |  |  |  |
| SEERSEE  | ļ            | 05-  |  |  | -  |

|  | FOREIGN PATENT DOCUMENTS                |   |  |  |   |                  |
|--|---|---|--|--|---|------------------|
| Examiner<br>Initials*                    | Cite<br>No.1                            | Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> ) | Publication Date<br>MM-DD-YYYY   | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear | T <sub>6</sub>   |
| 4935000000000000000000000000000000000000 | 008000000000000000000000000000000000000 |   |  |  | **************************************  | <sub>6</sub> 206 |
|  |   | 000000000000000000000000000000000000000   |  | **************************************             | OORSOOKIGOOKIGOOKIGOOKIGOOKIGOOKIGOOKIGOOKI                                     |                  |
|  |   |   | OSTROOMISTORES STATES S | 000000   |   |                  |
|  |   |   |  | 999000000000000000000000000000000000000            | 550955550095000000000   |                  |
| 10500059059059                           | OND OF THE PROPERTY OF                  | g6650000  |  |  |   | odragon.         |

Examiner Signature /Kailash Srivastava/ Date Considered 09/04/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

102258.170US2

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/687,706 Filing Date INFORMATION DISCLOSURE 10/20/2003 STATEMENT BY APPLICANT First Named Inventor LOSCALZO, et al. Art Unit 1657 EXAMINER: Dr. K.C. Srivastava <del>105</del>1 (Use as many sheets as necessary) Examiner Name To Be Assigned

of

3

2

Attorney Docket Number

Sheet

|   |    | NON PATENT LITERATURE DOCUMENTS  |   |  |
|---|----|--|---|--|
| Examiner Initials* Cite                 |    | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |   |  |
| /K.S./                                  | AA | FRANCIOSA, Joseph A., "African-American Heart Failure Trial (A-HeFT): Rationale, Design, and Methodology," Journal of Cardiac Failure, Vol. 8, No. 3, 2002, pp. 128-135  |   |  |
|   | АВ | YANCY, Clyde W., et al., "Race and the Response to Adrenergic Blockage with Carvedilol in<br>Patients with Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp.<br>1358-1365   |   |  |
| 89,000,000,000                          | AC | YANCY, Clyde W., "Heart Failure in African Americans: A Cardiovascular Enigma," Journal of Cardiac Failure, Vol. 6, No. 3, 2000, pp. 183-186   | : |  |
| 200000000000000000000000000000000000000 | AD | EXNER, Derek V., et al., "Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1351-1357                       |   |  |
| 000000000000000000000000000000000000000 | AE | PACKER, Milton, et al., "Effect of Carvedilol on Survival in Severe Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1651-1658  |   |  |
| *************************************** | AF | "A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1659-1667  |   |  |
|   | AG | BRAUNWALD, Eugene, "Expanding Indications for Beta-Blockers in Heart Failure," N. Engl. J. Med., Vol. 344, No. 22, May 31, 2001, pp. 1711-1712   |   |  |
| фонорожно                               | АН | SCHWARTZ, Robert S., "Racial Profiling in Medical Research," N. Engl. J. Med., Vol. 344, No. 18, May 3, 2001, pp. 1392-1393  |   |  |
|   | AI | LEVINE, T. Barry, "Paradoxical Hypertension after Reversal of Heart Failure in Patients Treated with Intensive Vasodilator Therapy," American Journal of Hypertension, Ltd., 1998; 11:1041-1047  |   |  |
| /K.S./                                  | AJ | ABSTRACTS - Heart Failure 179A, JACC, February 1999  |   |  |

| Control of the Contro |  | <ul><li>(2) 他の面が他の対抗できるを試けてき、このできます。</li></ul>   | History Mountaint with Allie in Artains |                         |
|--|--|--|---|-------------------------|
|  | 1、1、1、1540年(1478年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)(1718年)  | 그 그 바쁜 그 옷도 잘 들었다.   | 4 T T T T T T T T T T T T T T T T T T T | 1/04/0000 I             |
| Examiner   | l 188 🖋 in 18 Nova i Reille i le 🗪 1981 et diff i le revidité de la vidité de la collège de la França de la collège de la França de la collège de la França de la collège de la Collè    | ・ ・ 医乳質能力 必ず しい しょうしんしょう おいみげき   | Date ()                                 | 3/04/2008 I             |
| LAaiiiiilei  | /Kailash Srivastava/ 🥒   |  | Date   Q.                               | <u>√</u> 11 ₩ ₩ ₩ ₩ ₩ ₩ |
| Cianatura  | /Naliasii Siivasiava/ 🦠  | TA CONTRACTOR OF THE CONTRACTO | Considered                              |                         |
| Signature  | terrore and a desire a desire a desire a desire de desire de de la constante d | 1.47   | Considered                              |                         |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known Application Number 10/687,706 INFORMATION DISCLOSURE Filing Date 10/20/2003 First Named Inventor STATEMENT BY APPLICANT LOSCALZO, et al. EXAMINER: Dr. K.C. Srivastava Art Unit **\*\*\*\*\*** 1657 (Use as many sheets as necessary) Examiner Name To Be Assigned Sheet Attorney Docket Number of 3 102258.170US2

|   |                   | NON PATENT LITERATURE DOCUMENTS   |        |  |
|---|-------------------|---|--------|--|
| Examiner Initials*  | Cite<br>No.1      | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |        |  |
| /K.S./  | AK                | KAHN, Jonathan, "How a Drug Becomes "Ethnic": Law, Commerce, and the Production of Racial Categories in Medicine," Yale Journal of Heath Policy, Law, and Ethics IV:1 (2004), pp. 1-46  |        |  |
| /K.S.   | AL                | PARKER, John D., et al., "The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin," The Journal of Pharmacology and Experimental Therapeutics, Vol. 280, No. 2, pp. 866-875   |        |  |
| /K.S./  | АМ                | KALINOWSKI, Leszek, et al., "Race-Specific Differences in Endothelial Function - Predisposition of African Americans to Vascular Diseases," Circulation, June 1, 2004, pp. 2511-2517  |        |  |
|   |                   |   |        |  |
|   |                   |   | ļ      |  |
|   |                   |   | ļ      |  |
|   |                   |   | ļ      |  |
|   |                   |   |        |  |
|   |                   |   |        |  |
|   |                   |   | ļ      |  |
| - AMERICAN CO   | Market Conference |   |        |  |
| SANDAR |                   |   | 300000 |  |
| Examiner<br>Signature   | /Kai              | llash Srivastava/ Date 09/04/2008   |        |  |

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.